Dalfampridine benefits ambulation but not cognition in multiple sclerosis.

Nikhil SatchidanandAllison DrakeA SmerbeckDavid HojnackiChanna KolbKara PatrickBianca Weinstock-GuttmanRobert W MotlRalph Hb Benedict

Published in: Multiple sclerosis (Houndmills, Basingstoke, England) (2018)

Dalfampridine benefits timed ambulation but not cognition. Some improvement among ambulation "responders" is consistent with prior reports of cognition-motor coupling in MS ( ClinicalTrials.gov #: NCT02006160).

Keyphrases

multiple sclerosis
white matter
mild cognitive impairment
mass spectrometry
ms ms
emergency department
adverse drug